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IL-2 ex vivo relative to ICOS Tregs. Functional analysis revealed
that ICOS+ Tregs secreted little IFN- and IL-2 in comparison to
CD4+Foxp3 – cells. Furthermore, analysis on 38 IL-2-treated
patients at MD Anderson, we found that non-responders had a
significantly higher degree of ICOS+ Treg expansion than respon-
ders during the first cycle of IL-2 therapy, while no significant
changes in the ICOS or bulk Treg population. In conclusion,
our data suggests that tracking changes in ICOS+ Tregs early
during the course of HD IL-2 therapy may be a new predictive
biomarker of clinical outcome.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.098
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Renal cell carcinoma (RCC) is the most widespread kidney
tumor, which originates mostly from distal kidney tubules. RCC
is the major mortality cause in excretory system cancer in adults,
and constitutes about 80% of various kidney cancers. The 5-year
survival rate is 60–70%, but lowers significantly in case of metas-
tasis formation. The tumor is relatively resistant to chemother-
apy and radiation therapy, but responds to immunotherapy.
Target drugs (e.g. sunitinib, bevacizumab, a-interferon, sorafenib)
are more preferable in RCC therapy. In most cases RCC is caused
by obesity, smoking, arterial hypertension and hereditary factors.
4 patients of Voronezh Regional Clinical Oncology Center, aged
from 50 to 75 years old were enrolled in this study. All were diag-
nosed with renal cell carcinoma confirmed by immunohisto-
chemical analysis.
Gene expression profiling was performed using Affymetrix
GeneAtlas system with Affymetrix Hunam Gene 1.1 ST DNA-
microarrays. Data moralization, statistical analysis and differen-
tially expressed genes (DEG) list creation were performed using
Partek Genomics Suite v. 6.6. DNA samples were sequenced on
Ion Proton sequencer with Comprehensive Cancer Panel primer
pool. Subsequent pathway analysis and biological interpretation
were conducted using Ingenuity Pathway Analysis system and
Ion Reporter Suite.
3528 genes were differentially expressed with expression
change more than 2 times, and 351 genes changed their expres-
sion more than 5 times (p-value <0.05).
Only mutations causing either amino-acid substitution in cor-
responding protein, open reading frame shift, or truncated tran-
script formation were taken into account. Targeted DNA
sequencing revealed 99 common mutations in normal tissues of
all test subjects. 14 mutations were localized in SDHB, TRIM33,
PDE4DIP, PBX1, ABL2, MTR, VHL, ROS1, PRKDC, CSMD3, MLLT10,
TRIP11, PER1, genes and were tumor-specific in all patients.
33 mutations were localized in promoter regions of EGFR, PDGFRA
and HNF1A genes.
The most representative metabolic and signaling pathways
according to Ingenuity knowledge base were ‘‘FXR/RXR
Activation”, ‘‘Atherosclerosis Signaling”, ‘‘LXR/RXR Activation”,
‘‘Production of NO and ROS in Macrophages”, ‘‘Cell migration
and adhesion”. Five most downregulated genes among all
patients were CALB1 (187), HPD (133), KNG1 (126), SLC36A2
(126) and PAH (122). Five most upregulated genes were
TNFAIP6 (+34), ANGPT2 (+23), SERPINE1 (+22), CP (+20), HILPDA
(+20).
Genes with mutations and differentially expressed genes were
simultaneously included in pathways analysis in order to gener-
ate gene networks with possible upstream regulators (mutated
genes) included. This allowed observing a number of gene inter-
actions not present in existing reports.
This method of genomic and transcriptomic data integration
allowed us to determine the sources of mRNA level variation. A
number of mutations and specific DEGs discovered in this study
are not registered in existing databases of annotated mutations,
which allows us to propose population heterogeneity of RCC
causes. These DNA mutations and mRNA level changes could
be used as predictive biomarkers of renal cell carcinoma.
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Background: Cancer cells attractive and activate many non-
tumoral cells, including bone marrow-derived cells, as a result
stimulate migration of this cells. Many studies demonstrate that
tumor causes active redistribution of bone marrow cells during
specific stages of cancer progression and metastasis. However,
to date how the bone marrow derived cells at primary sites is
hijacked to support tumor growth and how tumor progression
influence of bone marrow cells distribution is not understood.
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